Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment

Journal of Nephrology

Volumn 22, Issue 2, 2009, Pages 208-215

  Penne, E Lars ^a   Neumann, Jutta ^a   Klein, Inge H ^a   Oey, P Liam ^a   Bots, Michiel L ^a   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular diseases; Chronic kidney failure; Microneurography; Outcome; Renin angiotensin system; Sympathetic nervous system

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST;

ADRENERGIC TRANSMISSION; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERACTIVITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; STANDARD; SYMPATHETIC HYPERACTIVITY; SYSTOLIC BLOOD PRESSURE; ADRENERGIC SYSTEM; AUTONOMIC NEUROPATHY; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649402292     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918.
2. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003;14:3239-3244.
3. Kelm M, Schafer S, Mingers S, et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens. 1996;14:1357-1364.
4. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001;38:1711-1717.
5. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34:724-728.
6. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-1359.
7. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
8. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant. 2004;19:1354-1357.
9. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699-706.
10. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15:524-537.
11. Neumann J, Ligtenberg G, Klein IH, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int. 2004;65:1568-1576.
12. Matsukawa T, Gotoh E, Minamisawa K, et al. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol. 1991;261:R690-R696.
13. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763-E778.
14. Neumann J, Ligtenberg G, Klein IH, et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension. 2007;49:506-510.
15. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol. 2004;15:2902-2907.
16. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol. 2001;12:2427-2433.
17. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14:425-430.
18. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321-1328.
19. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev. 1979;59:919-957.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
21. Simons PC, Algra A, van de Laak MF, Grobbee DE. van der GY. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999;15:773-781.
22. Rupp H. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines? Curr Med Res Opin. 2007;23(Suppl 5):S25-S29.
23. Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J Physiol. 2000;528:407-417.
24. Song JH, Cha SH, Hong SB, Kim DH. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens Suppl. 2006;24:S101-S106.
25. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension. 2002;39:129-134.
26. Kasama S, Toyama T, Kumakura H, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med. 2003;44:884-890.
27. Grandi AM, Solbiati F, Laurita E, et al. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens. 2008;21:231-237.
28. Kunz R, Friedrich C, Wolbers M, Mann JFE. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30-48.
29. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438-1444.
30. Cice G, Di BA, D'Isa S, et al. Effect of telmisartan in addition to angiotensin converting enzyme inhibitors on morality and morbidity in haemodialysis patients with chronic heart failure: a double-blind placebo-controlled trial [abstract]. Nephrol Dial Transplant. 2005;20:v187.
31. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709-1717.
32. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719-734.
33. Zilch O, Vos PF, Oey PL, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens. 2007;25:1285-1289.